PGNY vs. TVTY, SHC, AGL, ARA, VMD, CO, OTRK, BRTX, MGRX, and MRAI
Should you be buying Progyny stock or one of its competitors? The main competitors of Progyny include Tivity Health (TVTY), Sotera Health (SHC), agilon health (AGL), American Renal Associates (ARA), Viemed Healthcare (VMD), Global Cord Blood (CO), Ontrak (OTRK), BioRestorative Therapies (BRTX), Mangoceuticals (MGRX), and Marpai (MRAI).
Progyny (NASDAQ:PGNY) and Tivity Health (NASDAQ:TVTY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership, community ranking and dividends.
Progyny currently has a consensus target price of $42.40, indicating a potential upside of 45.50%. Given Progyny's higher possible upside, equities analysts clearly believe Progyny is more favorable than Tivity Health.
94.9% of Progyny shares are owned by institutional investors. Comparatively, 91.5% of Tivity Health shares are owned by institutional investors. 12.3% of Progyny shares are owned by insiders. Comparatively, 2.0% of Tivity Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Tivity Health received 321 more outperform votes than Progyny when rated by MarketBeat users. However, 75.21% of users gave Progyny an outperform vote while only 54.03% of users gave Tivity Health an outperform vote.
Progyny has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Tivity Health has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500.
Tivity Health has lower revenue, but higher earnings than Progyny. Tivity Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.
Tivity Health has a net margin of 17.25% compared to Progyny's net margin of 5.53%. Tivity Health's return on equity of 75.94% beat Progyny's return on equity.
In the previous week, Progyny had 8 more articles in the media than Tivity Health. MarketBeat recorded 8 mentions for Progyny and 0 mentions for Tivity Health. Progyny's average media sentiment score of 0.53 beat Tivity Health's score of 0.00 indicating that Progyny is being referred to more favorably in the media.
Summary
Progyny beats Tivity Health on 9 of the 17 factors compared between the two stocks.
Get Progyny News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
